Trial Watch: Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma

Evidence stage: Later-Stage HumanRegulatory status: InvestigationalGuideline status: Not addressed

Important context

In plain English

The 30-second version

What happened?

ClinicalTrials.gov confirms that this Phase 4 study is registered and currently listed as Not Yet Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Why does it matter?

Phase 4 trials can contribute later-stage human evidence. CancerDiscoveries can track this record as results and regulatory information emerge.

What does this not prove?

A registered trial is not proof that the intervention works, is not FDA approval for this cancer or use, and is not a clinical-guideline recommendation.

Keep reading for evidence stage, limitations, study details, and sources.

What changed: ClinicalTrials.gov lists Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma (NCT07191379) as a Phase 4 interventional cancer study. The registry status is Not Yet Recruiting, with the record last updated 2026-10-21.

Study snapshot: Phase 4; Not Yet Recruiting; planned enrollment 50. Conditions listed: Multiple Myeloma in Relapse. A primary outcome listed by the registry is: To evaluate the feasibility of self-administration of SC daratumumab in the patients´ homes.

This entry tracks verified trial-registry facts. Trial registration by itself does not show that an intervention is effective, safe for a particular person, FDA-approved for this use, or recommended by clinical guidelines.

Population / Applicability

Studied in: Participants with Multiple Myeloma in Relapse who meet the study-specific registry eligibility criteria. (Unspecified)

Eligibility is study-specific. Registry information does not determine whether any individual should enroll in or receive the intervention.

Full evidence details
Study design
Other / not applicable
Sample size
50
Primary outcome
To evaluate the feasibility of self-administration of SC daratumumab in the patients´ homes
Replication
Unknown

Funding & Conflicts

ClinicalTrials.gov lists the lead sponsor as Odense University Hospital. Sponsorship is reported for transparency and does not establish efficacy.

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-10-21

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Guideline positions

Guideline

Position
Not addressed
Last verified
2026-10-21

Primary evidence supporting this story

Last reviewed

Related discoveries

Trial Watch: Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma

https://cancerdiscoveries.com/discoveries/trial-watch-self-administered-subcutaneous-daratumumab-in-patients-with-multiple-myeloma/

Evidence stage: Later-Stage Human

What This Means

ClinicalTrials.gov confirms that this Phase 4 study is registered and currently listed as Not Yet Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

What This Doesn't Mean

A registered trial is not proof that the intervention works, is not FDA approval for this cancer or use, and is not a clinical-guideline recommendation.

Why It Matters

Phase 4 trials can contribute later-stage human evidence. CancerDiscoveries can track this record as results and regulatory information emerge.

Important Limitations

  • Clinical-trial participation has study-specific eligibility criteria; registry listing does not mean a person qualifies or should enroll.

Primary sources

  • ClinicalTrials.gov — NCT07191379 — https://clinicaltrials.gov/study/NCT07191379 (NCT07191379)

Date verified: 2026-10-21

Correction status: No correction or retraction